ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Relacorilant (Lifyorli)

Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

Orphan
CHMP opinion 17 Sept 2026 · Corcept Therapeutics Netherlands B.V.
US · FDA approval, new medicine

Relacorilant (Lifyorli)

To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Approved 25 Mar 2026

Research

Diabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-02-20

Phase 3 randomised-withdrawal trial in adults with endogenous hypercortisolism: among 62 responders randomised, more patients with hypertension lost control on placebo than on continued relacorilant (difference 34%; OR 0.17). Acne and bursitis occurred only with relacorilant.

RCTn = 62
Pivonello et al. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.